Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Guido Rindi, Martyn E. Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski

Risultato della ricerca: Contributo in rivistaArticolo in rivista

513 Citazioni (Scopus)

Abstract

Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited.
Lingua originaleEnglish
pagine (da-a)224-233
Numero di pagine10
RivistaNew England Journal of Medicine
Volume371
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Aged
  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Diarrhea
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Gastrointestinal Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Peptides, Cyclic
  • Somatostatin

Fingerprint

Entra nei temi di ricerca di 'Lanreotide in metastatic enteropancreatic neuroendocrine tumors'. Insieme formano una fingerprint unica.

Cita questo